<table id="table3" width="95%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 3:  Clinically Significant Drug Interactions with KETEK</caption>
<col align="left" valign="top" width="38%"></col>
<col align="left" valign="top" width="30%"></col>
<col align="left" valign="top" width="32%"></col>
<tbody>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">Drugs That Are Affected By KETEK</content>
</td>
</tr>
<tr stylecode="Botrule">
<td align="center" stylecode="Lrule Rrule">
<content stylecode="bold">Drug(s) with Pharmacokinetics Affected by KETEK<br/>(Mechanism of interaction, if known)</content>
</td>
<td align="center" stylecode="Rrule">
<content stylecode="bold">Recommendation<br/>(Exposure)</content>
</td>
<td align="center" stylecode="Rrule">
<content stylecode="bold">Comments</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Cisapride<br/>(CYP3 A4 Substrate)</content>
</td>
<td stylecode="Rrule">
<content stylecode="bold">Contraindicated<br/>(Plasma exposure increased)</content>
</td>
<td stylecode="Rrule">Co-administration of cisapride with repeated doses of KETEK resulted in significant increases in QTc.<content stylecode="italics"> [see <linkhtml href="#S4.4">Contraindications (4.4)</linkhtml>]</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Pimozide<br/>(CYP3 A4 Substrate)</content>
</td>
<td stylecode="Rrule">
<content stylecode="bold">Contraindicated<br/>(Plasma exposure likely to be increased)</content>
</td>
<td stylecode="Rrule">Although there are no studies looking at the interaction between KETEK and pimozide, there is a potential risk of life-threatening QT prolongation. <content stylecode="italics">[see <linkhtml href="#S4.4">Contraindications (4.4)</linkhtml>]</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Colchicine</content>
<br/>
<br/>
<br/>
<content stylecode="bold">(CYP3 A4 and P-glycoprotein efflux transporter Substrate)</content>
</td>
<td stylecode="Rrule">
<content stylecode="bold">Contraindicated </content>in patients with renal or hepatic impairment.<br/>
<br/>
<content stylecode="bold">(Plasma exposure increased)</content>
</td>
<td stylecode="Rrule">Risk of life-threatening colchicine toxicity. If co-administration of KETEK and colchicine is necessary in patients with normal renal and hepatic function, reduce the dose of colchicine. Monitor for symptoms of colchicine toxicity.  <content stylecode="italics">[see <linkhtml href="#S4.5">Contraindications (4.5)</linkhtml>; <linkhtml href="#S5.5">Warnings and Precautions (5.5)</linkhtml>]</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Simvastatin, Lovastatin, and Atorvastatin (HMG-CoA Reductase Inhibitors metabolized by CYP3A4)<br/>(CYP3 A4 Substrate)</content>
</td>
<td stylecode="Rrule">
<content stylecode="bold">Avoid Use<br/>(Plasma exposure increased)</content>
</td>
<td stylecode="Rrule">High levels of HMG-CoA reductase inhibitors increase the risk of myopathy and rhabdomyolysis. Avoid concomitant use of simvastatin, lovastatin, or atorvastatin with KETEK. If KETEK is prescribed, suspend therapy with simvastatin, lovastatin, or atorvastatin during the course of KETEK. An interaction may occur with simvastatin, lovastatin or atorvastatin but not with statins which are not metabolized by CYP3A4.  <content stylecode="italics">[see <linkhtml href="#S5.5">Warnings and Precautions (5.5)</linkhtml>] </content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Ergot Alkaloids</content>
<br/>
</td>
<td stylecode="Rrule">
<content stylecode="bold"> Not Recommended<br/> (Plasma exposure likely to be increased)</content>
</td>
<td stylecode="Rrule">No specific drug interaction studies have been performed. However, acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia has been reported when macrolide antibiotics were co-administered with ergot alkaloid derivatives (such as ergotamine or dihydroergotamine). Without further data, the co-administration of KETEK and these drugs is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Calcium Channel Blockers<br/>(CYP3 A4 Substrate)</content>
<br/>
</td>
<td stylecode="Rrule">
<content stylecode="bold">Use with Caution<br/>(Plasma exposure increased)</content>
</td>
<td stylecode="Rrule">Hypotension, bradyarrhythmia, and loss of consciousness have been observed in patients receiving concomitant treatment with calcium channel blockers that are substrates of CYP 3A4 (e.g., verapamil, amlodipine, diltiazem). Monitor for these adverse reactions and toxicity related to calcium channel blockers and adjust calcium channel blocker dosage as necessary.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Midazolam<br/>(CYP3 A4 Substrate)</content>
<br/>
</td>
<td stylecode="Rrule">
<content stylecode="bold">Use with Caution<br/>(Plasma exposure likely to be increased)</content>
</td>
<td stylecode="Rrule">Monitor for benzodiazepine-related adverse reactions and adjust midazolam dosage if necessary. Use caution with other benzodiazepines, which are metabolized by CYP 3A4 and undergo a high first-pass effect (e.g., triazolam). </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Other drugs metabolized by CYP3A4, such as carbamazepine, cyclosporine, tacrolimus, sirolimus, hexobarbital, and phenytoin</content>
<br/>
<content stylecode="bold">(CYP3 A4 Substrates)</content>
</td>
<td stylecode="Rrule">
<content stylecode="bold">Use with Caution<br/>(Plasma exposure likely to be increased)</content>
</td>
<td stylecode="Rrule">No specific drug interaction studies have been performed to evaluate these drug-drug interactions with KETEK. However, increases or prolongation of the therapeutic and/or adverse effects of drugs metabolized by the cytochrome P450 system may be observed if administered with KETEK.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Metoprolol<br/>(CYP2D6 Substrate)</content>
</td>
<td stylecode="Rrule">
<content stylecode="bold">Use with Caution<br/>(Plasma exposure increased)</content>
</td>
<td stylecode="Rrule">Co-administration of KETEK and metoprolol in patients with heart failure could lead to metoprolol toxicity and should be considered with caution. Monitor for metoprolol toxicity and adjust metoprolol dosage.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Digoxin</content>
</td>
<td stylecode="Rrule">
<content stylecode="bold">Use with Caution<br/>(Plasma exposure increased)</content>
</td>
<td stylecode="Rrule">Monitor for digoxin side effects or serum levels during concomitant administration of digoxin and KETEK. </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Theophylline</content>
<br/>
</td>
<td stylecode="Rrule">
<content stylecode="bold">Use with Caution<br/>(Plasma exposure minimally increased)</content>
</td>
<td stylecode="Rrule">Co-administration of theophylline may worsen gastrointestinal effects such as nausea and vomiting, especially in female patients.   Administer theophylline and KETEK 1 hour apart to decrease the likelihood of gastrointestinal side effects.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Oral Anticoagulants</content>
</td>
<td stylecode="Rrule">
<content stylecode="bold">Use with Caution<br/>(Plasma exposure increased)</content>
</td>
<td stylecode="Rrule">Spontaneous post-marketing reports suggest that administration of KETEK and oral anticoagulants concomitantly may potentiate the effects of the oral anticoagulants. Consider monitoring prothrombin times/INR while patients are receiving KETEK and oral anticoagulants simultaneously.</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">Drugs that Affect KETEK</content>
</td>
</tr>
<tr stylecode="Botrule">
<td align="center" stylecode="Lrule Rrule">
<content stylecode="bold">Drug(s) that Affect the  Pharmacokinetics of KETEK</content>
</td>
<td align="center" stylecode="Rrule">
<content stylecode="bold">Recommendation</content>
</td>
<td align="center" stylecode="Rrule">
<content stylecode="bold">Comments </content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Rifampin<br/>(CYP3A4 Inducer)</content>
</td>
<td stylecode="Rrule">
<content stylecode="bold">Avoid Concomitant Use<br/>(Reduced KETEK exposure)</content>
</td>
<td stylecode="Rrule">Loss of KETEK effect is likely [<content stylecode="italics">see <linkhtml href="#S12.3">Clinical Pharmacology (12.3)</linkhtml>
</content>]</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Other CYP3A4 inducers (phenytoin, carbamazepine, or phenobarbital)</content>
</td>
<td stylecode="Rrule">
<content stylecode="bold">Avoid Concomitant Use<br/>(Reduced KETEK exposure)</content>
</td>
<td stylecode="Rrule">Loss of KETEK effect is likely [<content stylecode="italics">see <linkhtml href="#S12.3">Clinical Pharmacology (12.3)</linkhtml>
</content>]</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Itraconazole and Ketoconazole</content>
<br/>
</td>
<td stylecode="Rrule">
<content stylecode="bold">Avoid Concomitant Use<br/>(Increased KETEK exposure)</content>
</td>
<td stylecode="Rrule">Increased KETEK toxicity is likely [<content stylecode="italics">see <linkhtml href="#S12.3">Clinical Pharmacology (12.3)</linkhtml>
</content>]</td>
</tr>
</tbody>
</table>